Background--Normal or near-normal coronary arteries (NNCAs) or nonobstructive coronary artery disease (CAD) are found on invasive coronary angiography in %55% of patients. Some attribute this to frequent referral of low-risk patients. We sought to identify the referral indications, pretest risk, key clinical characteristics, sex, and outcomes in patients with NNCAs and nonobstructive CAD versus obstructive CAD on nonemergent invasive coronary angiography.
S
everal recent studies have highlighted the high prevalence of angiographically normal or near-normal coronary arteries (NNCAs) or nonobstructive coronary artery disease (CAD) in patients referred for diagnostic invasive coronary angiography (ICA) for suspected CAD. 1 Whereas some normal studies can be expected, the finding of more than 50% of diagnostic studies showing no obstructive CAD in many US cardiac catheterization laboratories has generated both interest and controversy. [1] [2] [3] Lack of awareness of, and adherence to, guideline-based appropriateness criteria are commonly proposed reasons for the variable diagnostic yield of ICA. 2 Past studies using administrative databases do not include accurate data on the reasons for referral of individual patients to ICA and coronary angiographic findings related to sex for each category of ICA indication. 4 Similarly, cardiac event rates in consecutive patients with NNCA and nonobstructive CAD versus obstructive CAD are not reported in these database studies. Moreover, the frequency and associated clinical, imaging, and biomarker correlates of the findings of NNCAs, nonobstructive CAD, and obstructive CAD at ICA have not been well studied.
In this present study, we determined the prevalence of NNCAs, nonobstructive CAD, and obstructive CAD and outcomes in a large number of consecutive symptomatic patients, including those with a non-ST-elevation myocardial infarction (NSTEMI), referred for nonemergent ICA. Indications for ICA, pretest risk, key clinical characteristics, sex differences, and appropriateness of ICA were also examined in detail.
Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request. We reviewed the medical records of 1579 consecutive patients aged ≥18 years who underwent an initial ICA at the University of Virginia (Charlottesville, VA) for suspected CAD between January 1, 2012 and December 31, 2013. Patients with known CAD or a history of myocardial infarction (MI; n=419) and those with emergent indications for ICA (n=68), such as an ST-elevation myocardial infarction, cardiogenic shock, or post-cardiac arrest were excluded. Patients undergoing preoperative evaluation before transplant (n=76) or cardiothoracic surgery (n=91) were also excluded. No patients who underwent ICA for nonischemic cardiomyopathy or congenital heart disease alone were included. The final study cohort comprised 925 patients. The University of Virginia Institutional Review Board gave approval for the study protocol and rendered waiver of informed consent.
Clinical Characteristics and Definitions of Terms
Key patient demographics, comorbidities, home medications, pertinent laboratory data, and stress test and imaging findings were prospectively entered into the electronic medical record for subsequent review. All data, including classification of symptoms, were collected from the medical record rather than through analysis of diagnostic codes or other administrative data to maximize accuracy. Atherosclerotic cardiovascular disease (ASCVD) risk score was calculated as the 10-year risk estimates from the pooled cohort equations. 5 An ASCVD risk score of ≥7.5% reflected elevated risk. 6 A diagnosis of a non-ST-elevation myocardial infarction (NSTEMI) was confirmed by an elevated peak troponin I (Abbot ARCHITECT; Abbott Diagnostics, Abbott Park, IL) within 30 days preceding ICA.
Stress Electrocardiography and Stress Imaging
Patients referred because of an abnormal stress test had undergone stress ECG alone, or in conjunction with echocardiography or perfusion imaging by quantitative gated singlephoton emission computed tomography (SPECT), 7 positron emission tomography (PET), or cardiac magnetic resonance imaging. Exercise and pharmacological stress and imaging protocols were standardized according to recommended guidelines with experienced readers rendering interpretations for the medical record. ECG evidence of ischemia was defined as horizontal or downsloping ST-segment depression of ≥1.0 mm measured 80 ms after the J-point for 3 consecutive beats. 8 Ischemia on imaging was defined as inducible wall motion abnormalities on stress echocardiography or reversible defects on myocardial perfusion imaging.
9-11 SPECT images were processed using a standard 17-segment model. Percentage of left ventricular (LV) ischemia was calculated as previously described. 12 High-risk ischemia was defined as ≥10% LV ischemia. 13 
Invasive Coronary Angiography
ICA was performed using standard clinical protocols with all angiograms interpreted by experienced invasive cardiologists. Our angiography laboratory participates in the National Cardiovascular Data Registry and adheres to its data-quality standards. An angiogram with NNCAs was defined as having ≤20% stenosis in all coronary vessels. The cutpoint of ≤20% was chosen in accord with some past studies in this area. 1, 2, 14 It is often difficult by ICA alone to distinguish patients with totally normal coronary arteries from those with minimal atherosclerotic plaques without either intravascular ultrasound or optical coherence tomography. For this reason, the label "near normal" is used because some of these patients may have minimal atherosclerosis. Nonobstructive and obstructive CAD were defined by at least 1 coronary artery with a 21% to 49% or ≥50% stenosis, respectively.
1,2,15
Because of the recognized interobserver variability of evaluating intermiediate stenoses, quantitative coronary analysis
Clinical Perspective
What Is New?
• A high rate of near-normal coronaries or nonobstructive coronary artery disease is consistently found in symptomatic patients referred for invasive coronary angiography irrespective of referral indication and despite high pretest risk and appropriate use.
• Women had a greater prevalence of near-normal coronary arteries or nonobstructive coronary artery disease across referral indications, but had similar low cardiac event rates.
What Are the Clinical Implications?
• These data suggest a potential for increased use of advanced noninvasive imaging evaluation to better characterize coronary anatomy and physiology before invasive angiography.
• Ongoing research is needed to better understand the pathophysiology of ischemia in symptomatic patients without obstructive coronary artery disease.
was retrospectively performed by an experienced angiographer, blinded to all clinical data, on patient studies in which stenosis of 21% to 69% was recorded on the clinical report.
Review of Indications for ICA
The predominant indication for ICA for each individual patient was identified by review of the medical record by 1 of 2 experienced reviewers blinded to the ICA results. When the reviewer was unsure of the indication after assessing the clinical record, both reviewers and the senior author examined the case and agreed upon the most likely indication for ICA. Referral indications included undiagnosed chest pain (CP) syndromes (stable and unstable angina), an abnormal stress test, NSTEMI with a documented troponin elevation, and heart failure of uncertain etiology.
Outcomes
Outcomes, including cardiac death, nonfatal MI, and late revascularization, were ascertained from the electronic medical record. In cases in which outcomes were uncertain or in subjects in whom follow-up was unavailable, telephone contact was made. Follow-up was complete in 923 subjects (99%). Events were classified by a reviewer blinded to the catheterization results. Cardiac death was defined as any death with a cardiac cause or without a clear noncardiac cause. Nonfatal MI was recorded for any troponin elevation ≥2 times the upper limit of normal, with or without typical ischemic electrocardiographic changes, in the setting of a history consistent with an acute coronary syndrome. Coronary revascularization procedures included percutaneous coronary interventions and coronary artery bypass grafting. Late revascularization was designated as any coronary revascularization performed ≥4 weeks after the initial coronary angiography.
Statistical Analysis
Continuous variables were presented as medians (25th, 75th percentiles) and were compared using Wilcoxon rank-sum and 
Results

Baseline Characteristics and Severity of Stenosis
Of the 925 patients in the study cohort, 287 (31.0%) had NNCAs, 125 (13.5%) had nonobstructive CAD, and 513 (55.5%) had obstructive CAD. Baseline characteristics of the patient population are provided in Table for the total cohort and divided by severity of angiographic stenosis. Although not all comparisons met statistical significance, patients with a lesser severity of coronary stenosis were younger and more likely to be female. They had a lower prevalence of peripheral and cerebrovascular disease and clinical risk factors for CAD.
Patients with NNCAs had a significantly higher body mass index than those with nonobstructive or obstructive CAD. A higher rate of aspirin usage was observed in patients with obstructive CAD. Statins were more commonly used in patients with any degree of CAD at the time of ICA referral.
There was a lower rate of CP or dyspnea thought to be an anginal equivalent in those without obstructive CAD. However, no difference was observed in severity of CP as gauged by a Canadian Cardiovascular Society Class of ≥III.
Median 10-year ASCVD risk for the entire study cohort was elevated at 17.8%. Table shows that subjects with obstructive CAD had the highest pretest ASCVD risk, although the majority of patients in all 3 stenosis subgroups had an elevated ASCVD risk of ≥7.5%. Men had a higher median 10-year ASCVD risk than women (19.9% versus 13.8%; P<0.001). Significantly more men than women had an elevated 10-year ASCVD risk score (81.1% versus 68.3%; P<0.001).
Indications for Referral for ICA
Indication for ICA was determined in all subjects. Figure 1 shows the prevalence of referral indications for ICA; an abnormal stress test (32.4%) was the most prevalent, followed by NSTEMI (27.9%). CP syndromes without a troponin elevation (stable and unstable angina) and heart failure were the primary indications for ICA in 23.8% and 13.0%, respectively. Other indications, such as ventricular tachycardia, made up a small minority of the patient cohort (2.9%). Figure 2 shows the prevalence of NNCAs, nonobstructive CAD, and obstructive CAD in all patients and subdivided by men versus women. Those referred to ICA after an abnormal stress test (with or without imaging) had a 42.1% rate of NNCAs or nonobstructive CAD. Those referred for ICA following an NSTEMI had a 27.9% rate of NNCAs or nonobstructive CAD, with a 2-fold higher rate of NNCAs (18.6%) compared with nonobstructive CAD (9.3%). Stenosis severity varied significantly by sex (P<0.001). Women had more NNCA (37.7% versus 25.7%; P<0.001) and NNCAs+nonobstructive CAD (53.5% versus 37.2%; P<0.001). Women had a lower rate of obstructive CAD for each indication ( Figure 2 ).
Coronary Angiographic Findings in Men and Women
Abnormal Stress Test Indication
Of the 300 patients referred for ICA after an abnormal stress test, 7 (2.3%) underwent exercise stress ECG testing without imaging. Of the remaining patients, 57 (19.0%) underwent stress echocardiography, 227 (75.7%) underwent exercise or pharmacological SPECT myocardial perfusion imaging, and 8 (2.7%) had either a PET or cardiac magnetic resonance stress perfusion study. One patient underwent computed tomographic (CT) angiography without stress. This patient was included in this referral group because of abnormal imaging findings warranting ICA. The majority of testing used pharmacological stress (63.3%).
Exercise or pharmacological stress imaging was performed in 292 patients, of whom 247 (84.6%) had ischemia and 20 (6.8%) had only evidence of infarction/scar. Surprisingly, patients exhibiting ischemia or ischemia with infarction/scar by imaging criteria had a 40.5% (100 of 247) rate of either NNCAs or nonobstructive CAD. Similarly, this rate was 55.0% (11 of 20) in patients with only imaging evidence of infarction/scar. Figure 3 illustrates the severity of angiographic stenosis according to stress ECG and stress imaging findings in the 217 patients with diagnostic stress ECGs. As shown, those with no ischemia by ECG or imaging criteria had With respect to sex differences in subjects referred for an abnormal stress test, the incidence of NNCA or nonobstructive CAD was significantly higher in women (51.1%) compared with men (35.0%; P=0.005), despite similar rates of ischemia in women and men in this subgroup (88.0% versus 81.8%; P=0.14). Figure 4 depicts the severity of stenosis in the 152 patients who underwent stress SPECT myocardial perfusion imaging and were found to have either normal perfusion, fixed defects consistent with infarction, <10% LV ischemia, or ≥10% LV ischemia. Rate of NNCA was substantial in both those with mild-to-moderate ischemia encompassing <10% of the LV (29.5%) and severe ischemia involving ≥10% of the LV (20.0%). The 40 patients with severe ischemia had a significantly higher rate of obstructive CAD (75.0%) than the 112 subjects without high-risk ischemia (55.4%; P=0.029). Prevalence of obstructive CAD was even higher (91.7%) in the 12 patients with ≥20% LV ischemia. Prevalences of NNCA and nonobstructive CAD were similar in patients with normal perfusion and in patients with solely fixed perfusion defects with no ischemia.
NSTEMI Indication
Of the 258 patients referred for NSTEMI, 48 (18.6%) had NNCAs, 24 (9.3%) had nonobstructive CAD, and 186 (72.1%) had obstructive CAD. Median troponin level was higher in NSTEMI patients with obstructive CAD (2.6 ng/mL; interquartile range, 0.5-6.7), compared with those with an NSTEMI, but NNCAs or nonobstructive CAD (0.7 ng/mL; interquartile range, 0.2-2.2; P<0.001). Nearly 90% of NSTEMI patients with a high troponin level (≥5.0 ng/mL) had obstructive CAD (62 of 69 [89.9%]). There was substantial variation in troponin values relative to severity of stenosis in patients with troponin levels of <5.0 ng/mL. Severity of coronary stenosis differed significantly between women and men referred for ICA for an NSTEMI (P=0.032). Women had higher rates of both NNCA (23.4% versus 15.2%) and nonobstructive CAD (13.1% versus 6.6%) compared with men. Women with NSTEMI had a lower rate of obstructive CAD (63.6% versus 78.8%; P=0.007). Female sex decreased the predictive power of the troponin value (P<0.001 for interaction by logistic regression).
CP (Stable and Unstable Angina) Indication
Of the 220 patients referred for CP syndromes without an elevated troponin and without an abnormal stress test preceding ICA, 119 had unstable angina and 101 had stable angina. There was no statistically significant difference in severity of stenosis between those with unstable and stable angina (P=0.11). Of patients referred for ICA for a CP syndrome, 41.4% had NNCAs, 14.1% had nonobstructive CAD, and 44.6% had obstructive CAD. Anginal severity did not impact the degree of coronary stenosis, as reflected by a Figure 3 . Severity of coronary artery stenosis in the 217 patients who underwent imaging before ICA and had an interpretable stress ECG subdivided according to absence or presence of ischemia by stress ECG and stress imaging criteria. Prevalence of obstructive CAD (≥50% stenosis) was highest in patients exhibiting ischemia on both the stress ECG and imaging (P<0.001) and lowest with both negative (P=0.015). CAD indicates coronary artery disease; ICA, invasive coronary angiography.
60.9% prevalence of NNCAs or nonobstructive CAD, in patients with severe angina as defined by a Canadian Cardiovascular Society score of ≥3.
As shown in Figure 6 , patients with stable or unstable angina who had an elevated 10-year ASCVD risk of ≥7.5% had a higher prevalence of obstructive CAD (48.6%) compared with those with a <7.5% 10-year ASCVD risk (30.4%; P=0.032). Compared with men, fewer women referred for a CP syndrome had elevated ASCVD risk (67.7% versus 82.8%; P=0.017). However, of those women with elevated risk, 58.7% had NNCA or nonobstructive CAD (compared with 45.5% for men; P=0.12).
The rate of normal arteries or NNCAs was very high (65.2%) in patients with an ASCVD risk of <7.5%. Female patients with CP syndromes in this group had a lesser degree of angiographic coronary stenosis than men (P=0.048). Prevalence of NNCA or nonobstructive CAD in patients with <7.5% ASCVD risk was 63.6% in women and 47.3% in men (P=0.015).
Heart Failure Indication
Of the 120 patients referred to ICA with heart failure of uncertain etiology, 47 (39.2%) had NNCAs, 26 (21.7%) had nonobstructive CAD, and 47 (39.2%) had obstructive CAD. The majority of patients in this group had systolic heart failure (81.3%). There was no difference in severity of coronary stenosis by type of heart failure (P=0.33). In this referral indication subgroup, women had a 76.1% prevalence of NNCAs or nonobstructive CAD versus 51.4% for men (P=0.007).
Appropriateness of ICA
Appropriateness of ICA in patients without NSTEMI from this cohort was reported previously in a research letter. 16 For this current expanded patient population, which included 258 NSTEMI patients, ICA was classified as appropriate in 918 patients (99.2%). The 7 patients with inappropriate indications for ICA all had NNCAs.
Outcomes
Median follow-up was 2.0 years. In those referred for abnormal stress, NSTEMI, or clinical CP syndromes, KaplanMeier survival analysis showed a significant decrease in survival free from cardiac death and nonfatal MI and free of all cardiac events for those with obstructive CAD in both men and women ( Figure 7A and 7B) compared with patients with NNCAs and nonobstructive CAD. Findings were similar when the analysis was limited to those with a high-risk troponin ≥1 ng/mL or ischemia on stress testing ( Figure 7C ). In the entire cohort, sex was not a significant predictor of cardiac events (P=0.84) when assessed by Cox proportional hazards analysis. More specifically, there was no difference in outcomes for men versus women with NNCAs, nonobstructive CAD, or obstructive CAD in the entire study cohort. Moreover, logistic regression showed no interaction between sex and severity of coronary stenosis (P=0.37). Patients with NNCAs and nonobstructive CAD had an excellent prognosis with no difference in event rates between these 2 subgroups. Annual cardiac death and nonfatal MI rates were 1.0% and 1.1%, Figure 6 . Severity of coronary stenosis in the 186 patients with stable or unstable angina referred for invasive coronary angiography. The group is subdivided by 10-year ASCVD risk of ≥7.5% (n=140) and <7.5% (n=46). Although the prevalence of obstructive CAD was greater in the subgroup with elevated pretest 10-year ASCVD risk (P=0.032), more than 50% had either normal/near-normal coronary arteries (≤20% stenosis) or nonobstructive CAD (21-49% stenosis). ASCVD, atherosclerotic cardiovascular disease; CAD, coronary artery disease. *P<0.05. Figure 7 . Kaplan-Meier survival curves of freedom from cardiac death and nonfatal myocardial infarction (MI) (A) and freedom from cardiac events (cardiac death, nonfatal MI, and late revascularization) (B) in those referred for abnormal stress, NSTEMI, or CP syndrome with NNCAs, nonobstructive CAD, and obstructive CAD stratified by sex. C, Freedom from cardiac events in high-risk patients with ischemia on stress testing or a troponin level ≥1 ng/mL. There was a consistently higher risk of events for those with obstructive CAD across all groups. CAD indicates coronary artery disease; CP, chest pain; NNCAs, near-normal coronary arteries; NSTEMI, non-ST-elevation myocardial infarction.
respectively, for patients with NNCAs and nonobstructive CAD (P=0.83). In contrast, the annual cardiac death+nonfatal MI rate was much higher in those with obstructive CAD (6.7%; P<0.001 versus NNCAs+nonobstructive CAD). The difference in annual event rates was even higher for all cardiac events (11.1% for obstructive CAD versus 1.1% for NNCAs+nonob-structive CAD; P<0.001).
Discussion
Data derived from large registries have reported an %40% rate of NNCAs in patients referred for elective diagnostic coronary angiography. 1,2 Douglas et al reported that the hospital variability in the rate of finding obstructive CAD at elective coronary angiography varied from 23% to 100%, with a median rate of 45% for the 691 US hospitals surveyed. 2 Prevalence of obstructive CAD in our cohort was 55.5%, somewhat higher than this median value. Rates of NNCAs and nonobstructive CAD in our cohort were 31% and 13.5%, respectively.
Referral to ICA for an Abnormal Stress Test
An abnormal stress test, predominantly with cardiac imaging, was the most common indication for referral to ICA in our cohort. Only 9% of the patients referred after stress testing had no ischemia or infarction by stress ECG or imaging criteria. These patients all had other abnormal findings at stress testing. Median ASCVD score was high (17.7%) for patients referred after a positive stress test, and nearly 75% were classified as having a high-risk score (≥7.5%). Despite the high pretest ASCVD risk and few nonischemic stress test results, only 60% of the patients with a positive stress test had obstructive CAD. This value is substantially higher than the 41% prevalence of obstructive CAD in the National Cardiovascular Data Registry database study of patients who underwent stress testing before ICA. 1 This does not necessarily imply that the remaining 40% of patients with NNCAs or nonobstructive CAD did not have abnormal coronary flow physiology. In fact, 25% of patients with ≥10% LV ischemia had NNCAs or nonobstructive CAD. These findings are consistent with the concept that a stenosis of ≥50% is not an accurate gold standard for abnormal coronary flow physiology. Microvascular or endothelial dysfunction may play a role in angina symptoms and ischemic changes on stress testing. 17 Consistent with this concept, nearly 50% of women in our study with abnormal stress tests had either NNCAs or nonobstructive CAD compared with 33% of men.
18
Referral to ICA for an NSTEMI Of 258 patients referred for ICA for an NSTEMI, 72 (28%) had NNCAs or nonobstructive CAD. Patients with the highest troponin levels (≥5.0 ng/mL) had a high prevalence of obstructive CAD. A substantially larger rate of NNCAs or nonobstructive CAD was observed in those with lower troponin levels. Nearly 50% of patients considered to have borderline troponin elevations and 40% of those with low troponin levels had NNCA or nonobstructive CAD. Although some of these patients may have had etiologies other than an acute coronary syndrome as the cause of an elevated troponin level, most had symptoms and/or ECG changes consistent with an NSTEMI. Again, more women than men were observed to have an NSTEMI with NNCAs or nonobstructive CAD. Other past studies in the literature have shown variable rates of nonobstructive CAD or NNCAs in women with an NSTEMI.
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Referral to ICA for Stable or Unstable Angina
Unstable and stable CP syndromes comprised the next most common indications for ICA. Despite a high pretest 10-year ASCVD risk for both CP groups, prevalence of NNCAs or nonobstructive CAD was substantial in both the stable angina (60%) and unstable angina (50%) groups. As expected, the higher the pretest 10-year ASCVD risk, the higher the rate of obstructive CAD. However, it should be noted that slightly more than 50% of patients with elevated pretest 10-year ASCVD risk scores had NNCAs or nonobstructive CAD. Female subjects with stable or unstable angina had a significantly higher prevalence of NNCAs or nonobstructive CAD compared with male subjects (see Figure 2 ). Nearly two thirds of women referred for CP syndromes without a troponin elevation had NNCAs or nonobstructive CAD. This is consistent with previous observations of women presenting with angina having lessobstructive CAD than men. 20 Interestingly, the percentage of CP patients with severe angina, as assessed by the Canadian Cardiovascular Society Class ≥III, was not different between patients with obstructive CAD versus those with either NNCA or nonobstructive CAD. 
Pretest Clinical Risk and Appropriateness of ICA Referral
Sex Differences and Outcomes
Women represented a significant percentage (44%) of the patients referred for ICA in this study. For every indication for ICA described, women had a greater percentage of NNCAs or nonobstructive CAD than men. For the entire group of women spanning the various indications for ICA, 38% had NNCAs and 16% had nonobstructive CAD. Women and men had similar prevalence and extent of ischemia and troponin elevations, suggesting that different degrees of objective ischemic findings were not present by sex. Nearly 50% of women who underwent ICA for stable or unstable angina with no previous stress testing had NNCAs. This finding is not surprising, given that recent studies have shown that women present with more atypical symptoms than men and have less-obstructive CAD at angiography. 19, 20, 22 It is likely that microvascular dysfunction was the pathophysiological mechanism for angina in many of the women without obstructive CAD. Microvascular dysfunction can now be identified noninvasively by demonstrating abnormal flow reserve by PET or magnetic resonance imaging perfusion imaging. 23 Women without obstructive CAD and impaired coronary flow reserve by PET have a greater risk of future cardiovascular events than women with preserved flow reserve, and a greater risk than men with either normal or abnormal flow reserve. 24 Past studies have conflicting results on whether there is a difference in cardiac outcomes by sex in those with NNCAs, nonobstructive CAD, or obstructive CAD. An analysis of 5632 subjects in the prospective CONFIRM (Coronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter) Registry found no significant difference in risk of the composite end point of all-cause mortality and nonfatal MI by sex over 5 years. Likewise, a study of a registry of 11 223 subjects in Eastern Denmark found no Cox model interaction between sex and extent of CAD for major adverse cardiac events, which was defined as cardiovascular death, MI, stroke, heart failure, or all-cause mortality. 25, 26 In contrast to the CONFIRM and Denmark analyses, Sedlak et al found a 3-fold increased risk of major adverse cardiac events at 1 year for women versus men with nonobstructive CAD in 13 695 subjects in Canada. 27 Major adverse cardiac events in this study was defined as all-cause mortality, nonfatal MI or stroke, and heart failure admission. In our study, event-free survival was similar between women and men in those with NNCAs, nonobstructive CAD, and obstructive CAD. It should be pointed out that the rate of cardiac death and nonfatal MI was low in both men and women. A potential explanation for this finding is the use of medications with proven cardiovascular risk reduction, including aspirin and statins, in a substantial proportion of our population. 28 It also provides additional prognostic information attributed to the identification of nonobstructive CAD. 29 Moreover, given that the entire vessel wall is imaged with CT angiography as opposed to the lumen analysis by ICA, patients with near-normal coronaries can be separated from those with no coronary plaque, a group with a better prognosis. CT angiography might also be used in patients with an equivocal stress test or an unexpected positive test in a patient with a low pretest likelihood of CAD. 28 PET or magnetic resonance imaging perfusion imaging can ascertain abnormal flow reserve for identification of patients with microvascular dysfunction, particularly in women with symptoms suggestive of ischemia. 30 Hybrid imaging combining SPECT or PET with CT angiography can be utilized for this approach if abnormal flow reserve is detected. If no epicardial disease is observed in the setting of abnormal flow reserve by PET or magnetic resonance imaging, then microvascular or endothelial dysfunction in the absence of obstructive epicardial CAD may be proposed as the cause of symptoms or ischemia. Noninvasive stress imaging to rule out ischemia could be undertaken in patients with a low-to-intermediate risk of an acute coronary syndrome associated with a borderline elevated troponin level. 31 With greater utilization of noninvasive imaging technology, the rate of NNCAs could be reduced in patients with heart failure referred to ICA to rule out CAD.
Study Limitations
There are several limitations of this study. First, this is a single-center study. Although collection of clinical information, noninvasive test data, and laboratory data was comprehensive and not solely derived from registry or claims data, this study was retrospective in nature and not all data were collected in all patients. Symptom review was, at times, challenging, particularly gauging the severity of angina, which is an inherent limitation to retrospective analysis. However, the higher likelihood of disease in this cohort referred for angiography compared with the entire population undergoing stress testing and the added evaluation by clinicians in the catheterization laboratory may increase the accuracy. Moreover, severity of angina did not impact degree of stenosis identified. Rate of obstructive CAD in patients undergoing elective ICA in this study (55%) was somewhat higher than the median rate (45%) found at ICA in the analysis of US hospitals participating in the National Cardiovascular Data Registry Registry. 1 This may be attributed to fewer low-risk patients undergoing ICA and the inclusion of patients with NSTEMI in our study. Another limitation is that the functional significance of coronary artery stenoses was not routinely assessed by fractional flow reserve measurements at ICA. Plaque burden and diffuse disease could not be quantified because intravascular ultrasound measurements were not routinely made and these patients did not receive optical coherence tomography. Without use of these advanced plaque-imaging techniques, it is not possible to differentiate between those with 1% to 20% plaque and those with no coronary plaque, a group with a better prognosis. This may have led to an overestimation of risk and events in the NNCA group, though the event rates were very low (annual cardiac death and nonfatal MI rate of 1.0%). Given the challenge in predicting the angiographic site of likely future events, it is possible that a small intraluminal plaque of ≤20% stenosis could serve as a culprit lesion for a future event. We did retrospectively perform quantitative angiography in patients with intermediate stenosis to enhance the correct classification into those with 21% to 49% stenosis versus those with ≥50% stenosis. Also, a longer duration of follow-up might yield greater differences in event rates between patients with NNCAs versus those with nonobstructive CAD, especially given the high rates of antiatherosclerotic therapy use (53.2% on aspirin, 47.3% on a statin).
Conclusions
In conclusion, this study of consecutive patients, most with a high pre-ICA risk of CAD and appropriate referral for nonemergent ICA, showed a high prevalence (44.5%) of normal arteries or NNCAs or nonobstructive CAD. For each major referral indication (ie, an abnormal stress test, NSTEMI, stable or unstable CP syndrome, or heart failure), women had a greater prevalence of NNCAs or nonobstructive CAD than men. The short-term prognosis of patients with NNCAs and nonobstructive CAD was excellent compared with those with obstructive CAD. No sex differences were noted in cardiac event rates related to stenosis severity. Research in many centers is ongoing to better understand the pathophysiological mechanisms for ischemia (eg, coronary microvascular dysfunction) in such symptomatic patients with no obstructive CAD. 32 Reduction in the referral of symptomatic patients with NNCAs to ICA, and the identification of patients with nonobstructive CAD, may be accomplished by use of coronary CT angiography. Detection of abnormal coronary flow reserve in conjuction with NNCAs or nonobstructive CAD can be identified using hybrid imaging with PET-CT. 32 
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